Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Akero Therapeutics' Phase 2b results for efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4) due to MASH

Ticker(s): AKRO

Who's the expert?

Institution: Massachusetts General Hospital

Director of Hepatology and Liver Center & Vice Chief of Gastroenterology at Massachusetts General Hospital.
Treats 75 patients with PSC and 400 patients with NASH.
Research interest in liver disease pathogenesis in persons with HIV, viral hepatitis, and defining biomarkers and gene signatures for persons at high risk for liver disease progression and liver cancer.

Interview Goal

This conversation will focus on the current treatment landscape and the use of efruxifermin for patients with MASH.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.